Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis

Advances in Experimental Medicine and Biology

Volumn 568, Issue , 2005, Pages 217-223

  Kelly, Dominic F ^a   Rappuoli, Rino ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL TOXIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE M1; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYSACCHARIDE; PROTEIN GNA1162; PROTEIN GNA1220; PROTEIN GNA1946; PROTEIN GNA2001; PROTEIN GNA2132; PROTEIN GNA33; PROTEIN GNA992; TRANSFERASE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL ANTIGEN; BACTERIAL VACCINE;

ALLOPATHY; AMINO ACID SEQUENCE; CODING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOGENICITY; IN VITRO STUDY; MEDICAL RESEARCH; MICROORGANISM; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCREENING; SEROLOGY; ARTICLE; DRUG EFFECT; EPIDEMIC MENINGITIS; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PROTEOMICS;

ANIMALIA; NEISSERIA MENINGITIDIS;

ANTIGENS, BACTERIAL; BACTERIAL VACCINES; HUMANS; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEOMICS;

EID: 25144433296     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-25342-4_15     Document Type: Review

References (24)

1. Adamou, J.E., Heinrichs, J.H., Erwin, A.L. et al. (2001). Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69(2), 949-958.
2. Adu-Bobie, J., Lupetti, P., Brunelli, B. et al. (2004). GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect. Immun. 72(4), 1914-1919.
3. Capecchi, B., Serruto, D., Adu-Bobie, J., Rappuoli, R., and Pizza, M. (2004). The genome revolution in vaccine research. Curr. Issues Mol. Biol. 6(1), 17-27.
4. Comanducci, M., Bambini, S., Brunelli, B. et al. (2002). NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195(11), 1445-1454.
5. Cox, A.D., Wright, J.C., Li, J., Hood, D.W., Moxon, E.R. and Richards, J.C. (2003). Phosphorylation of the lipid A region of meningococcal lipopolysaccharide: Identification of a family of transferases that add phosphoethanolamine to lipopolysaccharide. J. Bacteriol. 185(11), 3270-3277.
6. De Groot, A.S. and Rappuoli, R. (2004). Genome-derived vaccines. Expert Rev. Vaccines 3(1), 59-76.
7. Etz, H., Minh, D.B., Henics, T. et al. (2002). Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. U S A 99(10), 6573-6578.
8. Fleischmann, R.D., Adams, M.D., White, O. et al. (1995). Whole-genome random sequencing and assembly of Haemophilus influenza Rd. Science 269(5223), 496-512.
9. Granoff, D.M., Moe, G.R., Giuliani, M.M. et al. (2001). A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J. Immunol. 167(11), 6487-6496.
10. Grifantini, R., Bartolini, E., Muzzi, A. et al. (2002). Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol. 20(9), 914-921.
11. Litt, D.J., Savino, S., Beddek, A. et al. (2004). Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis. 190(8), 1488-1497.
12. Maiden, M.C., Bygraves, J.A., Feil, E. et al. (1998). Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. U S A 95(6), 3140-3145.
13. Masignani, V., Balducci, E., Di Marcello, F. et al. (2003). NarE: A novel ADP-ribosyltransferase from Neisseria meningitidis. Mol. Microbiol. 50(3), 1055-1067.
14. Morley, S.L. and Pollard, A.J. (2001). Vaccine prevention of meningococcal disease, coming soon? Vaccine 20(5-6), 666-687.
15. Oliver, K.J., Reddin, K.M., Bracegirdle, P. et al. (2002). Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70(7), 3621-3626.
16. Pizza, M., Scarlato, V., Masignani, V. et al. (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820.
17. Poolman, J. and Berthet, F.X. (2001). Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 20 (Suppl 1), S24-S26.
18. Spratt, B.G. and Maiden, M.C. (1999). Bacterial population genetics, evolution and epidemiology. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354(1384), 701-710.
19. Tettelin, H., Masignani, V., Cieslewicz, M.J. et al. (2002). Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl. Acad. Sci. U S A 99(19), 12391-12396.
20. Tettelin, H., Saunders, N.J., Heidelberg, J. et al. (2000). Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459), 1809-1815.
21. Urwin, R., Russell, J.E., Thompson, E.A., Holmes, E.C., Feavers, I.M., Maiden, M.C. (2004). Distribution of surface protein variants among hyperinvasive meningococci: Implications for vaccine design. Infect. Immun. 72(10), 5955-5962.
22. Welsch, J.A. and Granoff, D. (2004). Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect. Immun. 72(10), 5903-5909.
23. Welsch, J.A., Moe, G.R., Rossi, R., Adu-Bobie, J., Rappuoli, R., Granoff, D.M. (2003). Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188(11), 1730-1740.
24. Wizemann, T.M., Heinrichs, J.H., Adamou, J.E. et al. (2001). Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69(3), 1593-1598.